The stock will trade on ASCO 2026 data (May 29-June 2) and the Q3 2026 dosing study initiation, not on the quarterly loss. Monitor for interim analysis readout from FORTIFI-HN01 expected mid-2027. The $539.8M cash position removes near-term financing risk.
Price Chart
Executive Summary
Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by increased R&D spend on the FORTIFI-HN01 pivotal trial. The company has $539.8M in cash, extended runway into H1 2029, and announced key clinical and executive milestones including a planned Q3 2026 randomized dosing study and ASCO 2026 data presentation. This is a pre-revenue clinical-stage biotech — the widening loss is expected and not a surprise; the stock will move on clinical catalysts, not quarterly financials.
Key Financial Metrics
Key Facts
- Net loss of $56.2M for Q1 2026 vs $36.8M in Q1 2025
- Cash, cash equivalents and marketable securities of $539.8M as of March 31, 2026
- Cash runway extended into first half of 2029
- Plan to initiate randomized study of loading + Q3W maintenance dosing in Q3 2026
- Long-term follow-up data from Phase 1b to be presented at ASCO 2026 (May 29-June 2)
- Bill Schelman promoted to CMO; Chris Sarchi appointed as Chief Commercial Officer
- R&D expenses $47.5M in Q1 2026 vs $34.3M in Q1 2025
- Net loss per share $-0.93 vs $-0.68 in prior year period
Financial Impact
Net loss widened by $19.4M YoY to $56.2M; cash position $539.8M provides runway into H1 2029
Risk Factors
- Clinical trial failure or disappointing ASCO data
- Dilution risk if additional financing needed before potential approval
- Regulatory delays in dosing study or accelerated approval pathway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033135 |
| Document: bcax-20260511.htm | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index-headers.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135-index.html | 0001628280-26-033135 |
| Document: 0001628280-26-033135.txt | 0001628280-26-033135 |
| 8-K Data (Synthetic) | 0001628280-26-033135 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $24.73 $19.78 | ▼ −20.02% | ▼ −20.24% | $18.25 (−26.18%) |
Aug 14, 2026 7w ago | Press Release | $24.28 $23.20 | ▼ −4.45% | ▼ −2.46% | $18.25 (−24.81%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 11, 2026 7w ago | 8-K | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Aug 11, 2026 7w ago | Press Release | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Jul 14, 2026 11w ago | Insider Cluster | $28.10 $23.76 | ▼ −15.44% | ▼ −17.94% | $18.25 (−35.04%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.28 $29.68 | ▼ −39.47% | ▼ −37.58% | $18.25 (+14.22%) |
May 26, 2026 18w ago | Insider Cluster | $21.58 $26.34 | ▲ +22.06% | ▲ +23.96% | $18.25 (−15.41%) |
May 11, 2026 20w ago | 8-K | $22.92 $20.56 | ▼ −10.30% | ▼ −9.99% | $18.25 (−20.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access